Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 3,193	$ 84,978
Property, plant and improvements
Property and equipment, net	166,509	14,576
Improvements in process		1,430,839
Other assets
Other receivable	418,905	222,562
Note receivable - related party	44,859	44,859
Advances to CEN Biotech Ukraine LLC - related party	875,328	775,328
Deferred lease expense		217,210
Intangible assets, net	5,805,771	6,230,583
Total assets	7,314,565	9,020,935
Current liabilities
Accounts payable	206,521	92,842
Accounts payable – related parties		11,986
Loans payable	10,107,205	9,981,883
Loans payable – related parties	1,360,806	838,923
Convertible notes payable	3,597,760	1,461,979
Convertible notes payable- related parties	926,368	2,210,313
Accrued interest	6,860,494	4,540,692
Accrued interest – related parties	946,227	592,901
Accrued expenses	402,377	295,874
Total current liabilities	24,407,758	20,027,393
Patent acquisition liability	1,010,000	5,000,000
Loans payable – related parties, less current portion		300,000
Convertible notes, less current portion	1,545,887	2,208,193
Convertible notes - related parties, less current portion	1,612,313	500,000
Total liabilities	28,575,958	28,035,586
Commitments and contingencies
Shareholders’ deficit
Common stock; unlimited authorized shares; 25,473,363 and 25,131,843 issued and outstanding as of December 31, 2018 and 2017, respectively. No par value.
Additional paid-in capital	14,393,660	9,110,041
Accumulated deficit	(35,655,053)	(28,124,692)
Total shareholders’ deficit	(21,261,393)	(19,014,651)
Total liabilities and shareholders’ deficit	$ 7,314,565	$ 9,020,935